贝伐珠单抗联合化疗对铂类药敏感型复发性卵巢癌治疗的疗效和安全性分析

Analysis on the Efficacy and Safety of Bevacizumab Combined with Chemotherapy in treatment of Platinum Sensitive Recurrent Ovarian Cancer

目的:探讨贝伐珠单抗联合化疗治疗铂类药敏感型复发性卵巢癌的疗效和安全性分析,为临床治疗提供一定的参考价值.方法:选取2015年2月至2018年2月期间我院肿瘤科收治的铂类药敏感型复发性卵巢癌患者80例,常规治疗的患者设为对照组,贝伐珠单抗联合治疗设为试验组,治疗一段时间后比较两组的临床疗效、KP S评分以及不良反应情况.结果:试验组和对照组治疗后两组癌症控制率差异无统计学意义,但是癌症缓解率差异有统计学意义(P<0.05),试验组癌症缓解率高于对照组,同时发现两组患者药物的不良反应情况差异无统计学意义,治疗后试验组KP S评分高于对照组,差异有统计学意义(P<0.05).结论:贝伐珠单抗联合化疗治疗铂类药敏感型复发性卵巢癌有一定的临床疗效,患者耐受性较好,具有一定的临床指导价值.

Objective: To investigate the clinical efficacy and safety of Bevacizumab combined with chemotherapy in treatment of platinum sensitive recurrent ovarian cancer, and provide a certain reference for clinical treatment. Methods: 80 patients with platinum sensitive recurrent ovarian cancer selected from February 2015 to February 2018, and they were divided into control group and experimental group, which were treated with conventional therapy and bevacizumab combined treatment. After a period of treatment, the clinical efficacy, KPS score and adverse reaction of the two groups were observed. Results: There was no significant difference in cancer control rate between the experimental group and the control group, but the difference of the cancer remission rate was statistically significant (P<0.05). The rate of cancer remission in the experimental group was higher than that of the control group. And there was no significant difference in the adverse reaction of the two groups. The KPS score of the experimental group was higher than that of the control group. The difference was statistically significant (P<0.05). Conclusion: Bevacizumab combined with chemotherapy has certain clinical curative effect in treating platinum sensitive recurrent ovarian cancer, and the patient is well tolerated, so it has certain clinical reference value.